18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2026-04-29
Target enrollment:
Participant gender:
Summary
This project aims to evaluate the role of fully hybrid PET/MRI with 18F-PSMA and
multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically
significant prostate cancer (csPCa).
This prospective PET/MRI clinical evaluation will ideally reduce the number of false negative
findings, while at the same time, allowing also to reduce the number of unnecessary prostate
biopsies in patients with low-risk, clinically indolent PCa.
The demonstration that, compared to mpMRI alone, the use of PET/MRI with 18F-PSMA has a
superior diagnostic accuracy in detecting men with csPCa will strongly support the inclusion
of 18F-PSMA as pre-biopsy triage test, in addition to mpMRI in daily clinical practice.